← Product Code [CHL](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHL) · K252207 # ABL90 FLEX PLUS System, safeCLINITUBES (K252207) _Radiometer Medicals Aps · CHL · Apr 10, 2026 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHL/K252207 ## Device Facts - **Applicant:** Radiometer Medicals Aps - **Product Code:** [CHL](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHL.md) - **Decision Date:** Apr 10, 2026 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1120 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use The ABL90 FLEX PLUS System is an in vitro diagnostic, portable, automated analyzer that quantitatively measures: - blood gas (pCO2) in heparinized arterial, venous and capillary whole blood, and - pH and oximetry (ctHb) in heparinized capillary whole blood. The ABL90 FLEX PLUS System is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient, or point-of-care setting. These tests are only performed under a physician's order. pH and pCO2: pH and pCO2 measurements are used in the diagnosis and treatment of life-threatening acid-base disturbances. ctHb (Total Hemoglobin): Total hemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia in venous and arterial whole blood. Capillary whole blood is used to estimate the presence of ctHb. safeCLINITUBES are intended for the collection, mixing, and dispensing of capillary whole blood samples on the ABL90 FLEX PLUS System. ## Device Story The ABL90 FLEX PLUS System is a portable, automated in vitro diagnostic analyzer for blood gas and oximetry analysis. It accepts heparinized arterial, venous, or capillary whole blood samples. Capillary samples are collected using safeCLINITUBES. The device utilizes potentiometry (pH, pCO2) and spectrophotometry (ctHb) to analyze samples. The system features an automated sample inlet mechanism with specific modes for different sample types (S65 syringe, SP65 short probe, C65 capillary). Operated by trained technologists, nurses, physicians, or therapists in clinical or point-of-care settings, the device provides quantitative results to clinicians. These results are used to diagnose and treat life-threatening acid-base disturbances and detect anemia. The system aids clinical decision-making by providing rapid, accurate blood chemistry data at the point of care, potentially improving patient management in acute care environments. ## Clinical Evidence Bench testing only. Analytical performance was validated through precision studies (multi-day, multi-site, POC operators), linearity (CLSI EP06-A2), interference testing (CLSI EP07-ED3/EP37-ED1), and method comparison (CLSI EP09c-ED3). Precision for pCO2 in capillary mode showed SDs ranging from 1.207 to 2.770 mmHg. Method comparison against a comparator method for capillary samples yielded R² values of 0.93 (pH, pCO2) and 0.95 (ctHb). No clinical trials were required. ## Technological Characteristics The system uses potentiometric sensors for pH and pCO2 (Nernst equation) and spectrophotometry for ctHb. Consumables include a sensor cassette (SC) and solution pack (SP). Capillary samples are processed via safeCLINITUBES (70/100μL). The system is a portable, automated analyzer. Connectivity and software details are consistent with previously cleared versions (K240998). Sterilization and material specifications are maintained from the predicate. ## Regulatory Identification A blood gases (PCO2 , PO2 ) and blood pH test system is a device intended to measure certain gases in blood, serum, plasma or pH of blood, serum, and plasma. Measurements of blood gases (PCO2 , PO2 ) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances. ## Predicate Devices - ABL90 FLEX PLUS ([K160153](/device/K160153.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY ## I Background Information: A 510(k) Number K252207 B Applicant Radiometer Medicals ApS C Proprietary and Established Names ABL90 FLEX PLUS System, safeCLINITUBES D Regulatory Information | Product Code(s) | Classification | Regulation Section | Panel | | --- | --- | --- | --- | | CHL | Class II | 21 CFR 862.1120 - Blood Gases (PCO2, PO2) And Blood Ph Test System | CH - Clinical Chemistry | | GKR | Class II | 21 CFR 864.5620 - Automated hemoglobin system | HE - Hematology | | JKA | Class II | 21 CFR 862.1675 - Blood specimen collection device | CH - Clinical Chemistry | ## II Submission/Device Overview: A Purpose for Submission: Modification to a previously cleared device. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 www.fda.gov {1} B Measurand: 1. pH (acidity) 2. pCO2 (partial pressure of carbon dioxide) 3. ctHB (total hemoglobin concentration) C Type of Test: Quantitative - Sensors using Potentiometry for pH and pCO2 measurement; Spectrophotometry for the measurement of ctHb. III Intended Use/Indications for Use: A Intended Use(s): See Indications for Use below. B Indication(s) for Use: The ABL90 FLEX PLUS System is an in vitro diagnostic, portable, automated analyzer that quantitatively measures: - blood gas (pCO2) in heparinized arterial, venous and capillary whole blood, and - pH and oximetry (ctHb) in heparinized capillary whole blood. The ABL90 FLEX PLUS System is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient, or point-of-care setting. These tests are only performed under a physician's order. pH and pCO2: pH and pCO2 measurements are used in the diagnosis and treatment of life-threatening acid-base disturbances. ctHb (Total Hemoglobin): Total hemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia in venous and arterial whole blood. Capillary whole blood is used to estimate the presence of ctHb. safeCLINITUBES are intended for the collection, mixing, and dispensing of capillary whole blood samples on the ABL90 FLEX PLUS System. C Special Conditions for Use Statement(s): Rx - For Prescription Use Only D Special Instrument Requirements: ABL90 FLEX PLUS System K252207 - Page 2 of 10 {2} K252207 - Page 3 of 10 # IV Device/System Characteristics: ## A Device Description: The ABL90 FLEX PLUS System consists of the ABL90 FLEX PLUS analyzer, sensor cassette (SC) and solution pack (SP) consumables, and related accessories for the analyzer as described in K240998. This submission is for the addition of capillary heparinized whole blood samples for pH and ctHB, and for capillary, arterial and venous heparinized whole blood samples for pCO2. The ABL90 FLEX PLUS System has an automated sample inlet mechanism, which can collect arterial and venous whole blood through two different measuring modes: the S65 syringe mode and the SP65 short probe mode, and capillary whole blood through the C65 capillary mode. safeCLINITUBES are 70 and 100μL plastic capillary tubes with balanced heparin, mixing wires and end caps. The ABL90 FLEX PLUS System was cleared in K241037 for the quantitative measurement of cK+, cNa+, cCa2+, glucose and lactate using arterial and venous heparinized whole blood samples. The system was cleared for the quantitative measurement of pH, blood gas (pO2), Oximetry (sO2, ctHb, FO2Hb, FCOHb, FMetHb, and FHHb) using arterial and venous heparinized whole blood samples in K240998. ## B Principle of Operation: There are two different measuring principles employed by the ABL90 FLEX PLUS System: Potentiometry and spectrophotometry. - Potentiometry: The potential of an electrode chain is measured by a voltmeter and related to the concentration of the sample (the Nernst equation). The potentiometric measuring principle is applied in the pH and pCO2 sensors. - Spectrophotometry: Light passes through a cuvette that contains a hemolyzed blood sample. The absorption spectrum is used to calculate oximetry parameters. This measuring principle is used for ctHb. # V Substantial Equivalence Information: ## A Predicate Device Name(s): ABL90 FLEX PLUS ## B Predicate 510(k) Number(s): K160153 ## C Comparison with Predicate(s): | Device & Predicate Device(s): | K252207 | K160153 | | --- | --- | --- | | Device Trade Name | ABL90 FLEX PLUS System | ABL90 FLEX PLUS | | General Device Characteristic Similarities | | | | Intended Use/Indications For Use | In vitro diagnostic that quantitatively measures | Same | {3} | Device & Predicate Device(s): | K252207 | K160153 | | --- | --- | --- | | | pH, blood gases, and oximetry. | | | Intended Use and Environment | Intended for use by trained technologists, nurses, physicians, and therapists in a laboratory environment, near patient, or point-of-care setting. | Same | | Prescription/OTC Use | Prescription Use | Same | | General Device Characteristic Differences | | | | Sample type | Balanced heparinized capillary whole blood for pH, ctHb and PCO2 using the safeCLINITUBES | No capillary whole blood claim for pH, ctHb and PCO2 | VI Standards/Guidance Documents Referenced: Clinical and Laboratory Standards Institute (CLSI) EP05-A3 – Evaluation of Precision of Quantitative Measurement Procedures CLSI EP17-A2 2nd Edition – Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline CLSI EP06-2nd Edition – Evaluation of Linearity of Quantitative Measurement Procedures CLSI EP07-3rd Edition – Interference Testing in Clinical Chemistry CLSI EP09c 3rd Edition – Measurement Procedure Comparison and Bias Estimation Using Patient Samples CLSI EP37 1st Edition – Supplemental Tables for Interference Testing in Clinical Chemistry CLSI EP39 1st Edition – A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests VII Performance Characteristics (if/when applicable): A Analytical Performance: 1. Precision/Reproducibility: Point of care precision (aqueous control material): A multi-day precision study was performed at three point of care (POC) sites using four concentrations of aqueous control solutions. At each site, each level was tested as two replicates per run, two runs per day, for twenty days. At least three POC operators were K252207 - Page 4 of 10 {4} included at each site. Repeatability, within-laboratory precision, and reproducibility results are reported below: | Parameter | QC Level | N | Mean | Repeatability | | Within Lab-Precision | | Reproducibility | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | SD | CV% | SD | CV% | SD | CV% | | pCO2 (mmHg) | L 1 | 243* | 70.5 | 0.53 | 0.7 | 1.13 | 1.6 | 1.16 | 1.6 | | | L 2 | 244 | 42.7 | 0.23 | 0.5 | 0.5 | 1.2 | 0.50 | 1.2 | | | L 3 | 244 | 23.1 | 0.12 | 0.5 | 0.27 | 1.2 | 0.29 | 1.2 | | | L 4 | 244 | 97.3 | 1.17 | 1.2 | 1.81 | 1.9 | 2.08 | 2.1 | *One L1 sample replicate was excluded due to insufficient sample being loaded onto the instrument. Point of Care precision (Whole Blood) pCO2 in S65 and SP65 Mode: A multi-day precision study was performed at three sites by at least three POC operators at each site, using balanced heparinized whole blood targeted to levels within the reportable range of pCO2. The whole blood precision was assessed using duplicate test results collected across multiple point of care sites using both the S65 and SP65 sampling modes. Samples were grouped into subintervals based on their mean values. The results are summarized below. | Parameter (unit) | N | Test interval | Mean | Repeatability | | | --- | --- | --- | --- | --- | --- | | | | | | SD | CV% | | S65 Mode | | | | | | | pCO2 (mmHg) | 4 | 25 - <32 | 27.775 | 0.320 | 1.15 | | | 166 | 32 - <48 | 40.417 | 0.271 | 0.67 | | | 50 | 48 - <60 | 52.030 | 0.266 | 0.51 | | | 26 | 60 - <80 | 67.908 | 0.495 | 0.73 | | SP65 Mode | | | | | | | pCO2 (mmHg) | 4 | 25 - <32 | 29.375 | 1.005 | 3.42 | | | 160 | 32 - <48 | 40.448 | 0.168 | 0.42 | | | 50 | 48 - <60 | 51.742 | 0.231 | 0.45 | | | 27 | 60 - <80 | 68.989 | 0.334 | 0.48 | # Within Sample Precision - Capillary Mode Fingerstick A multi-day precision study to assess heparinized capillary whole blood sample within run precision in capillary mode was performed at two sites by at least two POC operators at each site. Capillary whole blood from 39 donors via finger stick puncture from two (2) fingers into 2 safeCLINITUBE capillary tubes was collected. Blood from each capillary pair was analyzed in singlet in capillary mode on one ABL90 FLEX PLUS analyzer. Samples were grouped into subintervals based on their mean values. The results are summarized below. K252207 - Page 5 of 10 {5} | Parameter (unit) | N | Test interval | Mean | Repeatability | | | --- | --- | --- | --- | --- | --- | | | | | | SD | CV% | | pH | 20 | 7.2 - <7.35 | 7.325 | 0.012 | 0.17 | | | 40 | 7.35 - <7.40 | 7.374 | 0.011 | 0.15 | | | 18 | 7.40 - <7.55 | 7.430 | 0.016 | 0.21 | | pCO2 (mmHg) | 6 | 25 - <35 | 32.233 | 1.626 | 5.04 | | | 58 | 35 - <48 | 41.002 | 1.207 | 2.94 | | | 14 | 48 - <60 | 51.636 | 2.770 | 5.36 | | ctHb (g/dL) | 30 | 8 - <13.5 | 11.487 | 0.285 | 2.48 | | | 46 | 13.5 - <17.5 | 14.930 | 0.248 | 1.66 | ## 2. Linearity: Linearity testing was conducted in general accordance with CLSI EP06-A2. The linearity of the ABL90 FLEX PLUS System test for pCO2 was evaluated by preparing balanced heparinized venous whole blood samples. To achieve target concentrations, samples for pCO2 were prepared via tonometry. At least 10 replicates were run for each level. The results are summarized below. Linearity for pH, and ctHb was previously established in K240998. | Parameter (units) | Reportable Range | Tested Range | Slope | Intercept | R2 | | --- | --- | --- | --- | --- | --- | | pC02 (mmHg) | 15.4-98.3 | 9.4 – 99.89 | 1.009 | 0 | 0.9995 | ## 3. Analytical Specificity/Interference: Interference testing was performed according to CLSI EP07-ED3 and CLSI EP37-ED1 and consisted of two parts: paired-difference testing and dose-response experiments. a. The paired-difference testing was conducted on all potential interferents. Matched samples were tested, one with no interferent and the other with the interferent. If no interference was found, no further testing was performed. b. The dose-response experiment was only conducted on interferents found to have an effect via the paired-difference testing. This was carried out to determine the concentration at which clinically significant interference occurred. Freshly drawn heparinized adult venous whole blood was used as starting material for the interference studies. Interference testing was conducted at two levels (i.e., low and high) for K252207 - Page 6 of 10 {6} pCO2. The following tables list the concentrations of each substance at which no significant interference was found. Highest concentration tested at which no significant interference is observed | Potential interferent for parameter pCO2 | Concentration | | --- | --- | | Bilirubin, conjugated | 40 mg/dL | | Bilirubin, unconjugated | 40 mg/dL | | Biotin | 3510 ng/mL | | Hemolysis | 20% | | Intralipid | 2000 mg/dL | | Propofol | 4.8 mg/dL | Interference for pH, and ctHb was previously established in K240998. ## 4. Assay Reportable Range: The reportable ranges are | Parameter | Unit | Reportable Range | | --- | --- | --- | | pH | pH Scale | 6.818 - 7.797 | | pCO2 | mmHg | 15.4 - 98.3 | | ctHb | g/dL | 0.1 - 24.0 | ## 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): pCO2: Traceable to the International System of Units (SI) via commercially available certified specialty medical gas standards. Refer to K240998 for traceability information for pH and ctHB ## 6. Detection Limit: Detection capability testing was conducted in general accordance with CLSI EP17-A2. To achieve target concentrations, heparinized venous whole blood samples for pCO2 were prepared via tonometry. Testing was performed on the ABL90 FLEX PLUS System using 3 reagent lots, 9 instruments, over the course of 9 days, using 4 independent samples, with at least 5 replicates/sample, and 60 replicates/reagent lot. | Parameter (units) | Reportable Range | LoQ results | | --- | --- | --- | | pCO2 (mmHg) | 15.4-98.3 mmHg | 8.9 | Detection limits for pH and ctHB were previously established in K240998 K252207 - Page 7 of 10 {7} 7. Assay Cut-Off: Not applicable. B Comparison Studies: 1. Method Comparison with Predicate Device: Method comparison for pCO2 using heparinized arterial and venous whole blood specimens in S65 and SP65 mode and for pH, pCO2, and ctHb in heparinized capillary whole blood samples in C65 mode on the ABL90 FLEX PLUS System was done in general accordance with CLSI EP09c-ED3. Heparinized arterial and venous whole blood specimens (maximum of 10% contrived) that spanned the measuring range were collected across 3 POC sites to evaluate pCO2 measurements. Capillary blood samples (maximum of 10% contrived) collected across 2 POC sites in 2 safeCLINITUBE capillary tubes, with at least two POC users per site was compared to arterial whole blood specimens tested on a comparator method. Specifically, each capillary whole blood sample was measured once on the candidate device in C65 mode and once on the comparator device. A comparison between the two measurements was performed using linear regression analysis. The regression analysis are summarized below. Method Comparison - pCO2 in Arterial and Venous Whole Blood | Parameter | n | Range Min | Range Max | Intercept | Slope | R2 | Medical decision level (MDL) | Bias at MDL | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | S65 | | | | | | | | | | pCO2 (mmHg) | 446 | 16.1 | 95 | 0.55 | 0.99 | 1.0 | 32 | 0.20 | | | | | | | | | 48 | 0.03 | | SP65 | | | | | | | | | | pCO2 (mmHg) | 429 | 16.3 | 97.1 | 0.60 | 0.99 | 1.0 | 32 | 0.21 | | | | | | | | | 48 | 0.02 | K252207 - Page 8 of 10 {8} Method comparison – capillary whole blood | Parameter | N | Intercept | Slope | R² | MDL | Bias at MDL | | --- | --- | --- | --- | --- | --- | --- | | pH (pH scale) | 115 | -0.118 | 1.01 | 0.93 | 7.35 | -0.01 | | | | | | | 7.45 | -0.01 | | pCO2 (mmHg) | 119 | 3.094 | 0.95 | 0.93 | 32 | 1.6 | | | | | | | 48 | 0.85 | | ctHb (g/dL) | 110 | 0.713 | 0.99 | 0.95 | 7 | 0.66 | | | | | | | 10 | 0.63 | | | | | | | 17.5 | 0.57 | | Parameter | N | Range Min | Range Max | MDL | Bias at MDL | | --- | --- | --- | --- | --- | --- | | pH | 115 | 6.87 | 7.78 | 7.35 | -0.01 | | | | | | 7.45 | -0.01 | | pCO2 (mmHg) | 119 | 17 | 92.9 | 32 | 1.6 | | | | | | 48 | 0.85 | | ctHb (g/dL) | 110 | 0.36 | 22 | 7 | 0.66 | | | | | | 10 | 0.63 | | | | | | 17.5 | 0.57 | 2. Matrix Comparison: Not applicable. C Clinical Studies: 1. Clinical Sensitivity: Not applicable. 2. Clinical Specificity: Not applicable. 3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable. D Clinical Cut-Off: Not applicable. K252207 - Page 9 of 10 {9} K252207 - Page 10 of 10 # E Expected Values/Reference Range: Below are general reference ranges, cited from literature, for a normal, healthy population. | Parameter | Unit | Reference range | | --- | --- | --- | | pCO2 | mmHg; Torr | 35-481 (male) 32-451 (female) | | | kPa | 4.67-6.401 (male) 4.27-6.001 (female) | | ctHb | (g/dL) | 13.5 – 17.53 (male) / 12.0 – 16.03 (female)^{2} | | pH | | 7.35 – 7.45^{1} | 1 Tietz NW, Logan NM. Reference ranges, In: Fundamentals of clinical chemistry. 3rd ed. Philadelphia: WB Saunders Company 1987: 944-75. 2 Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis: Saunders Elsevier, 2012. # VIII Proposed Labeling: The labeling supports the finding of substantial equivalence for this device. # IX Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHL/K252207](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/CHL/K252207) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com